For Appointments
(615) 832-5530
8:30 AM to 4:00 PM CST

Robert W. Herring, Jr.

M.D. F.A.C.P., F.A.C.G.

Dr. Robert W. Herring - Gastroenterologist

Robert W. Herring, Jr.

Dr. Robert W. Herring Jr. MD is a board certified gastroenterologist specializing in diagnosis and treatments of gastrointestinal and liver problems. He received his Doctor of Medicine degree from the University of Tennessee, Memphis in 1980. Dr. Herring has extensive experience in Internal Medicine and Gastroenterology. He earned his Gastroenterology and Hepatology Fellowship at Johns Hopkins University in 1985. Dr. Herring is a Fellow of the American College of Gastroenterology.

EDUCATIONAL BACKGROUND

  • John Overton High School, Nashville, Tennessee, 1972 GPA 4.00, Valedictorian
  • Bachelor of Science, Majors in Biology and Chemistry (Double), Birmingham-Southern College, Birmingham, Alabama, 1976 GPA 3.81, magna cum laude. Phi Beta Kappa Scholastic Honorary Fraternity
  • Doctor of Medicine, University of Tennessee, Memphis, Tennessee, 1980, GPA 3.62, cum laude. Alpha Omega Alpha Scholastic Honorary Fraternity
  • Residency in Internal Medicine, Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, North Carolina, 1980-1983
  • Fellowship in Gastroenterology and Hepatology, Johns Hopkins University, Baltimore, Maryland, 1983-1985

AWARDS AND HONORS

  • Salute to Excellence Award 2019, Nashville MidSouth Division, American Liver Foundation
  • Hepatologist of the Year Award 2016, Nashville MidSouth Division, American Liver Foundation, Nashville Division
  • President & Chairman of the Board, Board of Trustees, Nashville Mid South Division, American Liver Foundation, 2005 - 2019
  • Recognized as Doctorof Excellence and a Top Gastroenterologist of Tennessee, International Association of Healthcare Professionals, 2013
  • Americas Top Gastroenterologists, Consumers Research Council of America, 2012
  • Chairman, Medical Advisory Committee, Nashville Division, American Liver Foundation, 2003 - 2019
  • Physician Member, National Medical Advisory Committee, American Liver Foundation, 2013 - 2019

PUBLICATIONS & PRESENTATIONS

  • Keyur Patel,Stephen A. Harrison, Magdy Elkashab,James F. Trotter, Robert Herring,et al.“Cilofexor, aSelective NonsteroidalFXR Agonist,ReducesHepaticSteatosis, Serum Bile Acids, and Liver Biochemistryin Patientswith NASH”, Hepatology(accepted for publication)
  • Eric J. Lawitz, Edward Gane, Peter J. Ruane, Robert Herring, et al.“A Combination ofthe ACC Inhibitor GS-0976 (Firsocostat) and the Non-Steroidal FXR Agonist GS-9674 (Cilofexor) Improves Hepatic Steatosis, Biochemistry, and Stiffness in Patients with Nonalcoholic Steatohepatitis (NASH)”,Poster Presentation, Annual Meeting.European Association for the Study of the Liver,10–14 April 2019, Vienna, Austria
  • Newsome, Philip, Palmer, Melissa, Freilich, Bradley, Sheikh, Muhammad, Y., Sheikh, Aasim, Sarles, Harry, Herring, Robert, et al.“Safety tolerability and efficacy of volixibat, an apical sodium-dependent bile acid transporter inhibitor, in adults with non-alcoholic steatohepatitis: 24-week interim analysis results from a phase 2 study”, Abstract and PosterPresentation, Annual Meeting.European Association for the Study of the Liver,10–14April 2019, Vienna, Austria
  • Keyur Patel, Stephen A. Harrison, James F. Trotter, Robert Herring, et al. “The Nonsteroidal FXR Agonist GS-9674 Leads to Significant Reductions in Hepatic Steatosis, Serum Bile Acids, and Liver Biochemistry in a Phase 2,Randomized, Placebo-controlled Trial of Patients with NASH”, Abstract and Poster Presentation,Annual Meeting. American Association for the Study ofLiver Diseases, Hepatology, October2018, p438A.
  • Eric Lawitz, Robert Herring, et al. “Proof Of Concept Study Of An Apoptosis-Signal Regulating Kinase (Ask1) Inhibitor (selonsertib) In Combination With An Acetyl-Coa Carboxylase Inhibitor (GS-0976) Or A Farnesoid X Receptor (Fxr) Agonist (GS-9674) In Nash”, Abstract submitted to Digestive Disease Week (DDW) inWashington D.C. June 2018.
  • Stephen A. Harrison, Mazen Noureddin, Robert Herring, et al. “Preliminary Efficacy and Safety of Acetyl-COA Carboxylase(ACC) Inhibitor GS-0976 InPatients With Compensated Cirrhosis Due To Nash”, Poster Presentation, Annual Meeting. European Association for the Study of the Liver, April 2018.
  • Eric Lawitz, Robert Herring, et al. “Proof of Concept Study of an Apoptosis-Signal Regulating Kinase (Ask1) Inhibitor (Selonsertib) In Combination With An Acetyl-COA Carboxylase Inhibitor (GS-0976) or a Farnesoid X Receptor (FXR) Agonist (GS-9674) In NASH” , Abstract, Annual Meeting. European Association for the Study of the Liver, April 2018.
  • Manal F. Abdelmalek, Edgar D. Charles, Brent Neuschwander-Tetri, Dina Halegoua-DeMarzio, Arun Sanyal, Robert Herring, et al. “Baseline Serum Pro-C3 Predicts Response to BMS-986036 (peg-FGF21): A Secondary Analysis of a Multi-Center Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)”, Abstract 2112. Annual Meeting. American Association for the Study of Liver Diseases, October, 2017.
  • Eric Lawitz, Kris Kowdley,Michael Curry, Nancy Reau, Mindle Nguyen, Paul Kwo, Ira M. Jacobson, Tram Tran, Ronald Nahass, Frederico Hinestrosa, Robert Herring, et al. “High Efficacy of Sofosbuvir.Velpatasvir Plus GS-9857 for 12 Weeks in Treatment Experienced Genotype 1-6 HCV-Infected Patients, Including Those Previously Treated with Direct-Acting Antivirals” Supplement to The American Journal of Gastroenterology, October, 2016. Abstracts submitted for the 81st Annual Scientific Meeting of the American College of Gastroenterology. October 2016.
  • Eric Lawitz, Gary Matusow, Edwin DeJesus, Eric Yoshida, Franco Felizarta, Reem Ghalib, Eliot Godofsky, Robert Herring, et al. “Simeprevir plus sofosbuvir in patients with Chronic Hepatitis C Virus Genotype 1 Infection and Cirrhosis: A Phase 3Study (OPTIMIST -2)” Hepatology, Vol.64, No 2, 2016.
  • Eric Lawitz, Nancy Reau, Federico Hinestrosa, Mordechai Rabinovitz, Eugene Schiff, Aasim Sheikh, Ziad Younes, Robert Herring, Jr., et al. “Sofosbuvir, velpatasvir, and GS-9857 in patients with genotype2-6 hepatitis C virus infection: an open-label, phase2 trial.” Abstract Annual Meeting. European Association for the Study of the Liver, April 2016.
  • O’Leary J, Brown R, Reddy K, Tenkel J, Korenblat K, Younes Z, Herring R, et al. “Clinical Benefits of Successful Treatment in HCV Infected Patients with Decompensated Cirrhosis treatedwith sofosbuvir/Velpatasvir.” Abstract. Annual Meeting. European Association for theStudy of the Liver, April 2016.
  • Muir AJ, Poordad F, Lalezari J, Everson G, Dore GJ, Herring R, et al. “Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis.” Journal of the American Medical Association. 313 (17): 1736-1746, May 2015.
  • Eric Lawitz, Gary Matusow, Edwin DeJesus, Eric Yoshida, Franco Felizarta, Reem Ghalib, Eliot Godofsky, Robert Herring, et al. “ A Phase 3, open-label, single-arm study to evaluate the efficacy and safety of 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve or -experienced patients with chronic HCV genotype 1 infection and cirrhosis: OPTIMIST-2 .” Poster Presentation. Annual Meeting. European Association for the Study of the Liver, 2015.
  • Christophe Hézode, Robert Herring Jr, et al. “Effect of Baseline Factors on Response to the Fixed-Dose Combination of Daclatasvir, Asunaprevir, and Beclabuvir, With or Without Ribavirin, in Patients with HCV Genotype 1 Infection and Cirrhosis.” Poster Presentation. Annual Meeting. European Association for the Study of the Liver, 2015.
  • Lawitz E, Matusow G, DeJesus E, Yoshida E, Felizarta F, Ghalib R, Godofsky E, Herring R, et al. “A Phase 3, Open-Label, Single-Arm Study to evaluate the efficacy and safety of 12 weeks of Simeprevir plus Sofosbuvir in Treatment-Naïve or Experienced patients with Chronic Hepatitis C virus Genotype 1 infection and Cirrhosis: The Optimist-2 Study.” Abstract. Annual Meeting. European Association for the Study of the Liver, April, 2015.
  • Hezode C, Herring Jr., et al. “Effect of Baseline factors on response to the fixed-dose combination of Daclatasvir (DCF), Asunaprevir (ASV) and Beclabuvir (BCV), with or without Rivavirin (RBV), in patients with HCV Genotype 1 infection and Cirrhosis.” Abstract. Annual Meeting. European Association for the Study of the Liver, April, 2015.
  • Andrew J. Muir, Robert Herring, Jr., et al. “A Single Direct-Acting Anti-Viral Agent, ACH-3102, in Combination with Ribavirin is Able to Achieve SVR8 in Subjects with Genotype 1b Chronic Hepatitis C Infection.” Abstract. Annual Meeting. European Association for the Study of the Liver, 2013.
  • M. Sulkowski, M. Rodriguez-Torres, E Lawitz, M. Shiffman, S Pol, R Herring, et al. “High Sustained Viral Response in Treatment-Naïve HCV Genotype 1a and 1b Patients Treated for 12 Weeks with an Interferon-Free All-Oral Quad Regimen: Interim Results.” Poster Presentation. Annual Meeting. European Association for the Study of the Liver, April, 2012.
  • I Jacobson, E. Lawitz, J. Lalezari, I. Crespo, M. Davis, T. Hassanein, M. DeMicco, S. Arora, N. Gitlin, R. Herring, et al. “GS-7977 400 mg QD Safety and Tolerability in the Over 500 Patients Treated for 12 Weeks.” Poster Presentation. Annual Meeting. European Association for the Study of the Liver, April, 2012.
  • Wyles DL, Rodriguez-Torres M, Lawitz E, Shiffman ML, Pol S, Herring RW, et al. “All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naïve patients with genotype 1 HCV infection.” Hepatology. 60 (1): 56-64, July, 2014.
  • Wedemeyer, H., Jensen, D., Herring, Jr., et al. “PROPEL: A Randomized Trial of Mericitabine Plus Peginterferon Alpha-2a Therapy in Treatment-Naïve HCV Genotype 1/4 Patients.” Hepatology. 58 (2): 524-37, August, 2013.
  • Nezam Afdhal, M.D., K. Rajender Reddy, M.D., David R. Nelson, M.D., Eric Lawitz, M.D., Stuart C. Gordon, M.D., Eugene Schiff, M.D., Ronald Nahass, M.D., Reem Ghalib, M.D., Norman Gitlin, M.D., Robert Herring, M.D., et al. “Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection.” The New England Journal of Medicine. 17; 370 (16): 1483-93, April, 2014.
  • Kris V. Kowdley, M.D., Stuart C. Gordon, M.D., K. Rajender Reddy, M.D., Lorenzo Rossaro, M.D., David E. Bernstein, M.D., Eric Lawitz, M.D., Mitchell L. Shiffman, M.D., Eugene Schiff, M.D., Reem Ghalib, M.D., Michael Ryan, M.D., Vinod Rustgi, M.D., Mario Chojkier, M.D., Robert Herring, M.D., et al. Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis.” The New England Journal of Medicine. 15; 370 (20): 1879-88, April, 2014.
  • Jacobson IM, Gordon SC, Kowdley KV, Yoshidia EM, Rodriques-Torres M, Sulkowski MS, Shiffman ML, Lawitz E, Everson G, Bennett M, Schiff E, Al-Assi MT, Subramanian GM, An D, Lin M, McNally J, Brainard D, Symonds WT, McHutchison JG, Patel K, Feld J, Lianko S, Nelson DR, George J, Leggett B, Pianko S, Thompson A, Elkashab M, Ramji A, Swain M, Willems B, Yoshida E, Gane E, Stedman C, Afdhal N, Aggarwal A, Bank L, Beavers K, Bennett M, Chung R, Davis M, Elion R, Etzkorn K, Everson G, Freilich B, Galambos M, Gordon S, Hassanein T, Herring R Jr, et al. “Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.” New England Journal of Medicine. 16; 368 (20): 1867-77, May, 2013.
  • Pruitt, R.E., M.D., Gremillion, Daniel, M.D., Herring, Robert W., Jr., et al. "Safety and Tolerance of Oral 5-ASA (Asacol) in the Treatment of Ulcerative Colitis and Crohn’s Disease: Results of the US Multicenter Open-Label Study." Gastroenterology. 100: A 241, May, 1991.
  • DR Nelson, S Zeuzem, P Andreone, P Ferenci, R. Herring, et al. “Balapiravir Plus Peginterferon alfa-2a (40KD) and Ribavirin for the Treatment of Chronic Hepatitis C Genotype 1: Randomized, Double-Blind, Placebo-Controlled Phase 2 Study.” Annals of Hepatology. 11 (1): 15-31, January-February, 2012.
  • Gaglio PJ, Rodrigues-Torres M, Herring R, et al. “Racial differences in response rates to consensus interferon in HCV infected patient’s naïve to previous therapy.” Journal of Clinical Gastroenterology. 38 (7): 599-604, August, 2004.
  • Pruitt, Ron E., M.D., Gremillion, Daniel E., M.D., Herring, Robert W., Jr., et al. "Oral 5-ASA (Asacol) in the Treatment of Mild to Moderate Ulcerative Colitis (UC): The Nashville Experience." Journal of Tennessee Medical Association. 84: 237, 1991.
  • Herring, R.W., et al. “Effect of acute alcohol administration on erythrocyte aldehyde dehydrogenase activity in man.” Alcoholism: Clinical and Experimental Research. 10 (6): 41S-45S, 1986.
  • Robert W. Herring Jr., et al. “A Single Direct-Acting Anti-viral agent, ACH-3102, with Ribavirin Is Able to Achieve a Robust Anti-viral Response in Subjects with Genotype 1B Chronic Hepatitis C infection.” Late-Breaking Abstract. Annual Meeting. American Association for the Study of Liver Diseases, 2013.
  • Eric Yoshida, Mark Sulkowski, Edward Gane, Robert Herring, et al. “The Concordance Between SVR4, SVR12, and SVR24 in Patients With Chronic HCV Infection Who Received Treatment With Sofosbuvir (SOF) in Phase 3 Clinical Trials.” Poster Presentation. Annual Meeting. American Association for the Study of Liver Diseases, 2013.
  • M. Sulkowski, M. Rodriguez-Torres, E. Lawitz, M. Shiffman, S. Pol, R. Herring, et al. “Interim Sustained Virologic Response Rates in Treatment-Naïve HCV Genotype 1a and 1b Patients Treated for 12 or 24 Weeks with an Interferon-Free All-Oral Quad Regimen.” Poster Presentation. Annual Meeting. European Association for the Study of the Liver, April, 2012.
  • M. Sulkowski, M. Rodriguez-Torres, E. Lawitz, M. Shiffman, S. Pol, R. Herring, et al. “Complete SVR4 Rates in Treatment-Naïve HCV Genotype 1a and 1b Patients Treated with an Interferon-Free All-Oral Quad Regimen.” Poster Presentation. Annual Meeting. American Association for the Study of Liver Diseases, 2012.
  • Wedemeyer, H., Jensen, D., Herring, Jr., et al. “Efficacy and Safety of Mericitabine (MCB) in Combination with PegIFNɑ-2A/RBV in G1/4 Treatment Naïve RCV Patients: Final Analysis From the PROPEL Study.” Poster Presentation. Annual Meeting. European Association for the Study of the Liver, 2011.
  • Jensen, D., Wedemeyer, H., Herring Jr., et al. “High Rates of Early Viral Response, Promising Safety Profile and Lack of Resistance-Related Breakthrough in HCV GT 1/4 Patients Treated With RG7128 Plus PegIFN alfa-2a (40KD)/RBV: Planned Week 12 Interim Analysis from the PROPEL Study.” Poster Presentation. Annual Meeting. American Association for the Study of Liver Diseases, 2010.

ARTICLES

Additional articles that Dr. Herring has authored and co-authored are listed below, please click on the article to review the abstract of that study

  • All-oral combination of ledipasvir, vedroprevir,tegobuvir, and ribavirin in treatment-naïve patients with genotype 1 HCV infection
  • Read More

  • PROPEL: A Randomized Trail of Mericitabine Plus Peginterferon Alpha-2a Therapy in Treatment-Naïve HCV Genotype ¼ Patients
  • Read More

  • Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
  • Read More

  • Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
  • Read More

  • Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatement options
  • Read More

  • Safety and Tolerance of Oral 5-ASA (Asacol) in the treatment of Ulcerative Colitis and Crohn’s Disease: Results of the US Multicenter Open-Label Study
  • Read More

  • Balapiravir Plus Pegiterferon alfa-2a (40KD) and Ribavirin for the treatment of Chronic Hepatitis C Genotype 1: Randomized Double-Blind, Placebo-Controlled Phase 2 Study
  • Read More

  • Racial differences in response rates to consensus interferon in HCV infected patient’s naïve to previous therapy
  • Read More

  • Oral 5-ASA (Asacol) in the treatment of Mild to Moderate Ulcerative Colitis (UC): The Nashville Experience
  • Read More

  • Effect of acute alcohol administration on erythrocyte aldehyde dehydrogenase activity in man
  • Read More

PDF1Download CV


You will need the Adobe Reader to view and print these documents.Get Adobe Reader